IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
**Review Article**
October 2023 Vol.:28, Issue:3


# Human Prohibits of Bacillus Strains: Characterization, Safety, Microbiome, and Probiotic Carrier

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

**Elavarasi.E*, Dr.W.Helen, Puniparthi Sunitha**

*Bharath institute of higher education and research, India*

**Submitted:** 18 September 2023
**Accepted:** 23 September 2023
**Published:** 30 October 2023



**Keywords:** Bacillus Strains, Characterization, Safety, Microbiome, Probiotic Carrier

**ABSTRACT**

Bacillus strains have garnered attention as potential probiotics for human consumption due to their unique characteristics and health benefits. These spore-forming bacteria exhibit resilience against harsh environmental conditions, making them well-suited for survival in the digestive tract. Bacillus strains have demonstrated promising probiotic properties, including modulating gut microbiota, enhancing nutrient absorption, and stimulating the immune system. Several Bacillus species, such as Bacillus coagulans, Bacillus subtilis, and Bacillus clausii, have been extensively studied for their probiotic potential. Research suggests that these strains may contribute to improved digestive health, reduced gastrointestinal discomfort, and even the prevention of certain gastrointestinal disorders. Moreover, Bacillus strains have exhibited antimicrobial activity against pathogenic bacteria, adding an extra layer of protection to the gut. Furthermore, their spore-forming nature allows for long-term stability in probiotic formulations. In summary, Bacillus strains show promise as human probiotics, offering resilience, potential health benefits, and a valuable addition to the toolbox of probiotic options. However, further research is needed to fully elucidate their mechanisms of action and to establish specific recommendations for their use in promoting human health.

## INTRODUCTION:

Probiotics are living microorganisms that confer health benefits when consumed in adequate amounts. While Lactobacillus and Bifidobacterium are well-known probiotic genera, Bacillus strains have gained attention in recent years for their potential as human probiotics. This article explores the characterization, safety, microbiome interactions, and the introduction of innovative carriers for Bacillus-based probiotics.

### Characterization of Bacillus Strains:

### Genetic and Phenotypic Identification:

Bacillus strains must be accurately identified using genetic techniques, such as 16S rRNA sequencing, and characterized phenotypically to ensure their stability and functionality.

### Spore Formation:

Bacillus species are known for their ability to form spores, making them resilient to harsh environmental conditions, including the acidic environment of the stomach.

### Metabolic Activities:

Understanding the metabolic activities of Bacillus strains is crucial for predicting their effects on the host microbiome and overall health.

### Safety Assessment:

### Pathogenicity:

Rigorous safety assessments are essential to rule out any potential pathogenicity of Bacillus strains intended for human consumption.

### Antibiotic Resistance:

Monitoring antibiotic resistance profiles to ensure the strains are not a reservoir for resistance genes is essential.

### Toxicity and Allergenicity:

Comprehensive toxicological and allergenicity studies must be conducted to ascertain the safety of Bacillus strains.

**Interactions with the Human Microbiome:**

**Gut Microbiota Modulation:**

Understanding how Bacillus strains interact with the existing gut microbiota is crucial for assessing their potential benefits.

**Immunomodulation:**

Investigating the immunomodulatory effects of Bacillus probiotics can provide insights into their impact on the host's immune system.

**Short-Chain Fatty Acid Production:**

Bacillus strains may influence the production of short-chain fatty acids in the gut, which can have systemic health effects.

**Probiotic Carrier Introduction:**

**Innovative Delivery Systems:**

Encapsulation techniques, microencapsulation, and novel delivery systems can enhance the viability and efficacy of Bacillus probiotics.

**Targeted Delivery:**

Designing carriers that target specific regions of the gastrointestinal tract can optimize Bacillus strain delivery.

**Stability and Shelf-Life:**

Ensuring the stability and extended shelf-life of Bacillus probiotics is essential for commercial viability.

**Characterizing Bacillus probiotics:**

It is an essential aspect of understanding their potential benefits and applications. In this article, we will explore the key components of characterizing Bacillus probiotics, including their identification, safety assessment, functional properties, and applications.

**1. Taxonomic Identification:**

- The first step in characterizing Bacillus probiotics is to accurately identify and classify the strains. This involves molecular techniques such as 16S rRNA sequencing to determine their taxonomic position.

**2. Safety Assessment:**

- Safety is paramount when considering probiotics. Bacillus strains should be evaluated for their pathogenic potential through genome analysis and in vitro/in vivo studies.
- Assess their antibiotic resistance profiles to ensure they don't carry genes that confer resistance to clinically relevant antibiotics.
- Evaluate their potential for toxin production or adverse effects in humans.

**3. Functional Properties:**

- Probiotics must exhibit specific functional properties to be effective:
- **Survival and Viability:** Bacillus strains should be able to survive the harsh conditions of the gastrointestinal tract, including low pH and bile salts.
- **Adhesion and Colonization:** The ability to adhere to intestinal epithelial cells is crucial for colonization and efficacy.
- **Antimicrobial Activity:** Bacillus probiotics often produce antimicrobial compounds, such as bacteriocins, that can inhibit harmful pathogens.
- **Modulation of Immune Response:** Characterize their impact on the host immune system, including cytokine production and immune cell activation.
- **Production of Enzymes:** Some Bacillus strains produce beneficial enzymes like amylases, proteases, and lipases, which can aid in nutrient digestion.

**4. Functional Tests:**

- Conduct in vitro tests to evaluate specific functions, such as acid and bile tolerance, adhesion to epithelial cells, and production of antimicrobial compounds.
- Assess their ability to ferment prebiotic substrates and produce short-chain fatty acids (SCFAs) that promote gut health.

**5. Genomic Analysis:**

- Whole-genome sequencing can provide insights into the genetic makeup of Bacillus probiotics, including the presence of beneficial genes and potential virulence factors.

**6. Safety and Toxicity Studies:**

- Animal studies (in vivo) can help assess the safety of Bacillus probiotics, including any potential adverse effects.
- Investigate their impact on gut microbiota composition and function.

**7. Clinical Trials:**

- Conduct human clinical trials to evaluate the efficacy and safety of Bacillus probiotics in specific health conditions. This includes assessing their impact on digestive disorders, immune modulation, and other potential health benefits.

**8. Application-Specific Characterization:**

- Depending on the intended application (e.g., gut health, animal feed, agriculture), further characterization may be necessary to ensure Bacillus probiotics meet specific criteria.

**9. Formulation and Delivery:**

- Consider the formulation and delivery methods (e.g., capsules, powders, fermented foods) that will maximize probiotic viability and efficacy.

**10. Regulatory Compliance:**

- Ensure compliance with regulatory standards and guidelines for probiotics, which can vary by region.

Characterizing Bacillus probiotics involves a comprehensive approach encompassing taxonomic identification, safety assessment, functional properties, genomic analysis, and clinical evaluation. Thorough characterization is essential to unlocking the full potential of Bacillus probiotics for various health and industrial applications while ensuring their safety and efficacy.

**Bacillus cereus:**

Bacillus cereus is a ubiquitous, spore-forming bacterium commonly found in soil, dust, and various food products. While typically harmless, certain strains of B. cereus can cause food poisoning when ingested. This bacterium is notorious for causing two distinct types of foodborne illnesses: the emetic and diarrheal syndromes. The emetic syndrome is characterized by rapid-onset vomiting and is often associated with rice dishes that have been improperly stored or reheated. B. cereus produces a heat-stable toxin called cereulide, which triggers these symptoms.

Conversely, diarrheal syndrome results from the ingestion of B. cereus-contaminated foods, such as meats, vegetables, and dairy products. In this case, the bacterium produces enterotoxins in the intestines, leading to abdominal cramps and watery diarrhea within hours of consumption. Preventing B. cereus contamination involves proper food handling, storage, and hygiene practices. Adequate cooking, refrigeration, and reheating of foods are essential to minimize the risk of infection. While B. cereus is generally self-limiting and rarely fatal, it can cause discomfort and inconvenience, underscoring the importance of food safety measures to prevent its proliferation in our diets.

**Bacillus clausii:** Gut Health

Bacillus clausii is a unique and beneficial bacterium that has gained attention in the field of probiotics and microbiology. This spore-forming bacterium belongs to the Bacillus genus and is known for its resilience and therapeutic potential. Bacillus clausii spores have a remarkable ability to survive harsh environmental conditions, such as heat and acidity, making them ideal for use in oral probiotic supplements. When consumed, these spores can reach the intestines intact, where they become metabolically active, promoting a healthy gut microbiome.

Research suggests that Bacillus clausii can help restore gut balance, enhance digestion, and strengthen the immune system. It is often used to manage diarrhea, including antibiotic-associated diarrhea and infectious diarrhea, by outcompeting harmful pathogens in the gut. Furthermore, Bacillus clausii has shown promise in managing various gastrointestinal disorders, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Its safety profile and effectiveness make it a valuable option for individuals seeking natural ways to improve their gut health.

Bacillus clausii is a resilient and beneficial probiotic bacterium that offers promising health benefits for the digestive system. Its ability to survive harsh conditions and support gut health makes it a valuable addition to the world of probiotics and a subject of ongoing research.

**Bacillus coagulans:**

Bacillus coagulans is a remarkable probiotic bacterium that has gained popularity for its potential health benefits. Unlike many other probiotics, B. coagulans is a spore-forming bacterium, making it highly resilient and stable. This resilience allows it to survive harsh conditions, including the acidic environment of the stomach, ensuring its arrival in the gut intact. Studies suggest that B. coagulans may offer various health advantages. It can help maintain a healthy gut microbiome by promoting the growth of beneficial bacteria and inhibiting harmful ones. This balance in the gut flora can aid in digestion, alleviate gastrointestinal discomfort, and enhance nutrient absorption.B. coagulans have also been linked to immune system support. It may stimulate the production of immune cells, enhancing the body's defense mechanisms against pathogens.

Furthermore, this probiotic has shown promise in managing conditions such as irritable bowel syndrome (IBS), diarrhea, and even allergies. Its anti-inflammatory properties and ability to modulate the immune response make it a versatile player in promoting overall well-being.

Incorporating B. coagulans into your diet through supplements or probiotic-rich foods may be a proactive step towards maintaining digestive health and bolstering your immune system. However, it's essential to consult with a healthcare professional before adding any new supplement to your routine, especially if you have underlying health concerns.

**Bacillus licheniformis:**

Bacillus licheniformis is a Gram-positive, rod-shaped bacterium commonly found in soil and diverse environments. Known for its industrial significance, it produces various enzymes and metabolites with applications in biotechnology, agriculture, and food production. This versatile microorganism is used in the production of enzymes like amylases and proteases, which find uses in detergent and textile industries. Additionally, its ability to secrete antimicrobial compounds makes it a candidate for biocontrol in agriculture. Bacillus licheniformis exemplifies the valuable role of bacteria in harnessing natural processes for practical applications across multiple sectors.

**Bacillus polyfermenticus:**

Bacillus polyfermenticus is a fascinating Gram-positive bacterium renowned for its potential health benefits and industrial applications. Isolated from the human intestines, this probiotic microorganism has garnered attention for its probiotic properties. It aids in maintaining a balanced gut microbiome by promoting the growth of beneficial bacteria, which can enhance digestion and strengthen the immune system.

Beyond its role in human health, Bacillus polyfermenticus exhibits promise in various industrial applications. It produces enzymes like amylases and cellulases, which are essential in food processing, textile manufacturing, and biofuel production. Moreover, its ability to produce exopolysaccharides contributes to the development of biodegradable plastics and pharmaceutical formulations.

In summary, Bacillus polyfermenticus is a versatile bacterium with significant implications for both human health and industrial processes. Its probiotic potential and enzymatic capabilities underscore its importance in modern biotechnology and microbiology.

**Exploring the Versatility of Bacillus Species:**

Bacillus species are a diverse group of bacteria that have captured the attention of scientists and researchers worldwide. This article delves into the multifaceted world of Bacillus, highlighting their significance in various domains.

**1. Bacillus licheniformis: The Industrial Workhorse** Bacillus licheniformis stands out as an industrially vital bacterium, producing enzymes used in detergent and textile industries. Its antimicrobial properties also make it a potential player in biocontrol for agriculture.

**2. Bacillus polyfermenticus: A Probiotic Pioneer** Isolated from the human gut, Bacillus polyfermenticus has emerged as a probiotic powerhouse, promoting digestive health and bolstering immunity. Its diverse applications span beyond the gut, with contributions to biodegradable plastics and pharmaceuticals.

**3. Bacillus thuringiensis: Nature's Insecticide** This remarkable bacterium has become synonymous with biopesticides, owing to its ability to produce insecticidal proteins. Bacillus thuringiensis revolutionized pest control with its eco-friendly approach.

**4. Bacillus subtilis: A Model Organism** Bacillus subtilis serves as a model organism for scientific research. Its genetic tractability and robust physiology make it invaluable in studying cellular processes and biotechnological advancements.

**5. Bacillus cereus: A Foodborne Pathogen** Although often associated with foodborne illnesses, Bacillus cereus has a complex dual role as a pathogen and a potential source of industrially valuable enzymes.

**6. Bacillus in Biotechnology: A Promising Future** Bacillus species continue to pave the way for biotechnological innovations. Their enzyme production capabilities, probiotic potential, and eco-friendly applications position them as key players in shaping our future.

Bacillus bacteria, with their diverse attributes and applications, exemplify the profound impact of microorganisms on industry, agriculture, and health. Understanding these fascinating organisms opens up a world of possibilities for sustainable solutions and scientific breakthroughs.

**Safety on bacillus probiotics:**

Ensuring safety is paramount when using Bacillus probiotics. Careful strain selection is crucial, as not all Bacillus strains are safe for human consumption. Choose strains with a history of safe use and documented health benefits. Additionally, rigorous quality control during production and packaging is essential to prevent contamination. Dosage and usage instructions should be followed meticulously to avoid adverse effects, and individuals with compromised immune systems or underlying health conditions should consult healthcare professionals before starting Bacillus probiotics. Prioritizing safety measures helps harness the potential health benefits of Bacillus probiotics while minimizing any potential risks.

**Toxigenic potential of Bacillus species:**

The toxigenic potential of Bacillus species is an aspect that deserves close attention due to its implications for human health and food safety. While many Bacillus species offer significant benefits, some have the capacity to produce harmful toxins under certain conditions.

**Bacillus cereus** is a notable example. It is known for its ability to produce toxins responsible for foodborne illnesses, often linked to improperly stored or cooked foods. These toxins can

lead to symptoms ranging from mild gastrointestinal distress to more severe cases of food poisoning.

On the other hand, **Bacillus anthracis**, the causative agent of anthrax, produces a deadly toxin that poses a significant threat to both humans and animals.

Understanding the toxigenic potential of Bacillus species is essential. Rigorous food safety measures, including proper food storage and cooking practices, are necessary to prevent foodborne illnesses associated with Bacillus toxins. Additionally, the controlled use of beneficial Bacillus strains in probiotics and industrial applications, combined with strict quality control, helps minimize the risk of unintended toxin production. Research and vigilance in this area are vital to harnessing the positive attributes of Bacillus species while mitigating potential risks.

**Rising Threat of Antibiotic Resistance in Bacillus Species:**

Antibiotic resistance is a growing global concern that jeopardizes our ability to treat bacterial infections effectively. While much attention has been focused on pathogenic bacteria like Escherichia coli and Staphylococcus aureus, an often-overlooked group with significant antibiotic resistance potential is the Bacillus species.

Bacillus species are ubiquitous in nature and can be found in soil, water, and even the human gastrointestinal tract. Some strains, such as Bacillus anthracis and Bacillus cereus, can cause severe infections. Historically, antibiotics like penicillin and tetracycline have been effective against these bacteria. However, overuse and misuse of antibiotics have led to the emergence of antibiotic-resistant Bacillus strains.

Several mechanisms underlie Bacillus antibiotic resistance. These include the development of efflux pumps that actively remove antibiotics from bacterial cells, alterations in antibiotic targets, and the acquisition of resistance genes through horizontal gene transfer.

The potential consequences of antibiotic-resistant Bacillus strains are grave. They can lead to persistent infections that are difficult to treat, increased healthcare costs, and even mortality. Furthermore, these resistant strains may serve as reservoirs of resistance genes that can be transferred to other pathogenic bacteria, exacerbating the global antibiotic resistance crisis.

To combat this threat, a multifaceted approach is essential. This includes prudent antibiotic use in clinical and agricultural settings, surveillance of antibiotic resistance in Bacillus species, and the development of novel antibiotics and alternative treatment strategies. Only through a coordinated effort can we hope to mitigate the rising antibiotic resistance in Bacillus species and safeguard our ability to combat bacterial infections effectively.

**Biogenic amines (BA) Production:**

Biogenic amines are the area group of organic compounds that play essential roles in various biological processes, including neurotransmission, regulation of blood pressure, and immune response. These compounds are synthesized in living organisms through enzymatic processes and are crucial for maintaining physiological balance. Here, we explore the production of biogenic amines and their significance.

Biogenic amines are synthesized from amino acids, primarily tyrosine, tryptophan, and histidine. The enzymatic conversion of these amino acids into biogenic amines involves several steps and specific enzymes. For instance, dopamine and norepinephrine are derived from tyrosine, while serotonin originates from tryptophan. Histamine, on the other hand, is synthesized from histidine.

The production of biogenic amines is tightly regulated to ensure their optimal levels in the body. Dysregulation of these pathways can lead to various health issues. For instance, imbalances in dopamine and serotonin are associated with mood disorders like depression and anxiety. Likewise, disruptions in histamine production can lead to allergic reactions and inflammatory responses.

Biogenic amines also play a critical role in the food industry. Certain bacteria can produce biogenic amines in foods, such as cheese, fish, and wine, through the decarboxylation of amino acids. High levels of biogenic amines in food can pose health risks, including food poisoning and migraines, making their monitoring and control essential for food safety.

The production of biogenic amines is a complex and highly regulated process that influences various aspects of human health and well-being. Understanding these pathways is crucial for developing treatments for neurological disorders, managing allergies, and ensuring the safety of the food we consume. Further research in this field holds the promise of uncovering new therapeutic avenues and improving our overall quality of life.

**Unveiling the Potential of Bacillus Probiotics: A Microbiome Study**

**Introduction:** The human microbiome is a complex ecosystem of trillions of microorganisms inhabiting our bodies, playing a crucial role in our health and well-being. Among these microorganisms, Bacillus probiotics have gained attention for their potential health benefits. This article delves into a microbiome study focused on Bacillus probiotics, shedding light on their impact on the gut microbiome and overall health.

**Bacillus Probiotics:** Bacillus probiotics are a diverse group of spore-forming bacteria that have been used as dietary supplements to promote gut health. Unlike many other probiotics, Bacillus species can form highly resistant spores, allowing them to survive harsh conditions, such as stomach acid, and reach the intestines intact. Once in the intestines, they can germinate and exert their beneficial effects.

**Microbiome Study:** Recent research has shown that Bacillus probiotics can modulate the composition of the gut microbiome. They can stimulate the growth of beneficial bacteria like Bifidobacterium and Lactobacillus, which are known for their positive impact on digestion and immunity. Additionally, Bacillus probiotics have been shown to inhibit the growth of harmful pathogens like Clostridium difficile, reducing the risk of gastrointestinal infections.

Furthermore, Bacillus probiotics can produce short-chain fatty acids (SCFAs), such as butyrate, which serve as an energy source for colon cells and have anti-inflammatory properties. This can contribute to a healthier gut environment and may have far-reaching effects on overall health.

**Health Benefits:** The modulation of the gut microbiome by Bacillus probiotics has been associated with several health benefits. These may include improved digestion, enhanced immunity, and reduced inflammation. Some studies have even suggested potential applications in managing conditions like irritable bowel syndrome (IBS) and allergies.

The microbiome study on Bacillus probiotics underscores their potential to positively influence gut health and overall well-being. While more research is needed to fully understand their mechanisms of action and long-term effects, the findings so far are promising. Incorporating Bacillus probiotics into a balanced diet and lifestyle may offer a natural and effective way to support a healthy gut microbiome and promote better health.

The potential use of a Bacillus strain as a human probiotic holds promise, but it requires careful consideration across several critical dimensions: characterization, safety, microbiome interaction, and probiotic.

**Exploring Innovative Probiotic Carriers for Enhanced Delivery of Bacillus Probiotics:**

**Introduction:**

Probiotics, especially those of the Bacillus genus, have gained significant attention for their potential health benefits. These beneficial bacteria offer a range of advantages, from improving gut health to enhancing the immune system. However, one challenge in realizing their full potential is ensuring their survival and efficacy during transit through the harsh conditions of the gastrointestinal tract. To address this issue, innovative probiotic carriers have emerged as a promising solution.

**The Role of Probiotic Carriers:** Probiotic carriers serve as protective vehicles that shield Bacillus probiotics from the acidic environment of the stomach, ensuring their safe passage to the intestines. These carriers can come in various forms, each with unique advantages:

**Microencapsulation:** Microencapsulation involves enclosing Bacillus probiotics in protective shells or coatings. This technique not only shields the probiotics from gastric acid but also provides controlled release in the intestines, optimizing their efficacy.

**Prebiotic Fibers:** Prebiotic fibers serve as a nourishing substrate for Bacillus probiotics. They not only protect the probiotics but also promote their growth and colonization in the gut, enhancing their overall impact on gut health.

**Synbiotic Formulations:** Combining probiotics with prebiotics in synbiotic formulations creates a synergistic effect. This approach not only protects Bacillus probiotics during transit but also provides them with the necessary nutrients to thrive in the gut.

**Nanoparticles:** Nanoparticles offer an innovative approach to probiotic delivery. They can encapsulate Bacillus probiotics and protect them from harsh conditions, allowing for targeted release in specific parts of the digestive tract.

**Benefits of Innovative Probiotic Carriers:**

Utilizing these innovative carriers can significantly enhance the delivery and efficacy of Bacillus probiotics. They increase probiotic survival rates, improve gut colonization, and

enhance the overall health benefits. This is particularly important in addressing digestive disorders, boosting immunity, and promoting overall well-being.

Innovative probiotic carriers have the potential to revolutionize the field of probiotics, particularly Bacillus probiotics. By ensuring their safe passage through the digestive system and optimizing their delivery to the intestines, these carriers can unlock the full spectrum of health benefits offered by these beneficial bacteria. Further research and development in this field hold the promise of improving human health and well-being through enhanced probiotic delivery systems.

**CONCLUSION:**

Characterization of the Bacillus strain is paramount to ensure its efficacy as a probiotic. A comprehensive analysis of its genetic makeup, metabolic activities, and potential beneficial effects on the host is essential. This information aids in selecting strains with desirable probiotic properties, such as robustness in the gastrointestinal tract and production of beneficial metabolites.

Safety is a primary concern when evaluating any probiotic candidate. Extensive safety assessments are vital to confirm that the Bacillus strain does not pose any health risks, especially to vulnerable populations. Additionally, adherence to regulatory guidelines is crucial to guarantee the safety of human consumption.

Understanding the Bacillus strain's interaction with the human microbiome is fundamental. Probiotics should contribute positively to the composition and diversity of the gut microbiota. Research on how the strain modulates the microbiome and interacts with resident bacteria can provide valuable insights into its potential benefits.

The choice of a suitable probiotic carrier is pivotal in ensuring the viability and stability of the Bacillus strain throughout its journey to the gut. Proper encapsulation or delivery systems can protect the probiotic from harsh stomach conditions, enabling it to reach the intestines alive and functional.

Bacillus strains have demonstrated potential as human probiotics, but their characterization, safety, microbiome interactions, and choice of probiotic carriers are all critical considerations. Rigorous research and adherence to regulatory standards are essential to

harness the full potential of Bacillus strains as beneficial probiotics that can positively impact human health. Further studies and clinical trials will provide the necessary evidence to support their incorporation into human probiotic products.

## REFERENCES:


1. Abbrescia A, Palese LL, Papa S, Gaballo A, Alifano P, Sardanelli AM. Antibiotic sensitivity of *Bacillus clausii* strains in commercial preparation. *Curr. Med. Chem.* 2014;1:102–110. [Google Scholar]
2. Andersson A, Granum PE, Ronner U. The adhesion of *Bacillus cereus* spores to epithelial cells might be an additional virulence mechanism. *Int. J. Food Microbiol.* 1998;39:93–99. doi: 10.1016/S0168-1605(97)00121-9. [PubMed] [CrossRef] [Google Scholar]
3. Bernardeau M, Lehtinen MJ, Forssten SD, Nurminen P. Importance of the gastrointestinal life cycle of *Bacillus* for probiotic functionality. *J. Food Sci. Technol.* 2017;54:2570–2584. doi: 10.1007/s13197-017-2688-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Bozdogan B, Galopin S, Leclereq R. Characterization of a new erm-related macrolide resistance gene present in probiotic strains of *Bacillus clausii*. *Appl. Environ. Microbiol.* 2004;70:280–284. doi: 10.1128/AEM.70.1.280-284.2004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Calzada J, del Olmo A, Picon A, Gaya P, Nunez M. Reducing biogenic-amine-producing bacteria, decarboxylase activity, and biogenic amines in raw milk cheese by high-pressure treatments. *Appl. Environ. Microbiol.* 2013;79:1277–1283. doi: 10.1128/AEM.03368-12. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Casula G, Cutting SM. *Bacillus* probiotics: spore germination in the gastrointestinal tract. *Appl. Environ. Microbiol.* 2002; 68: 2344–2352. doi: 10.1128/AEM.68.5.2344-2352.2002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Chang M, Chang HC. Development of a screening method for biogenic amine producing *Bacillus* spp. *Int. J. Food Microbiol.* 2012;153:269–274. doi: 10.1016/j.ijfoodmicro.2011.11.008. [PubMed] [CrossRef] [Google Scholar]
8. Ciffo F. Determination of the spectrum of antibiotic resistance of the *Bacillus subtilis* strains of Enterogermina. *Chemioterapia.* 1984;3:45–52. [PubMed] [Google Scholar]
9. Chon JW, Kim JH, Lee SJ, Hyeon JY, Song KY, Park C, Seo KH. Prevalence, phenotypic traits and molecular characterization of emetic toxin-producing *Bacillus cereus* strains isolated from human stools in Korea. *J. Appl. Microbiol.* 2012;112:1042–1049. doi: 10.1111/j.1365-2672.2012.05277.x. [PubMed] [CrossRef] [Google Scholar]
10. Chudnovskaya NV, Ribalko SL, Sorokulova IB, Smirnov VV, Belyavskaya VA. Antiviral activity of *Bacillus probiotics*. Dopovidi. Nac. Acad. Nauk. Ukraini. 124-126 (1995)
11. Ciprandi G, Scordamaglia A, Ruffoni S, Pizzorno G, Canonica GW. Effects of an adjunctive treatment with *Bacillus subtilis* for food allergy. *Chemioterapia.* 1986;5:408–410. [PubMed] [Google Scholar]
12. Coton E, Coton M. Multiplex PCR for colony direct detection of gram-positive histamine-and tyramine-producing bacteria. *J. Microbiol. Methods.* 2005;63:296–304. doi: 10.1016/j.mimet.2005.04.001. [PubMed] [CrossRef] [Google Scholar]
13. Coton E, Coton M, Lucas P, Lonvaud A. Identification of the gene encoding a putative tyrosine decarboxylase of *Carnobacterium divergens* 508. *Food Microbiol.* 2004;21:125–130. doi: 10.1016/j.fm.2003.10.004. [CrossRef] [Google Scholar]
14. Cutting SM. *Bacillus* probiotics. *Food Microbiol.* 2011;28:214–220. doi: 10.1016/j.fm.2010.03.007. [PubMed] [CrossRef] [Google Scholar]
15. Dong TC, Van PH, Cutting SM. *Bacillus probiotics. Nutra Foods.* 2009;8:7–14. [Google Scholar]
16. Duc LH, Hong HA, Barbosa TM, Henriques AO, Cutting SM. Characterization of *Bacillus* probiotics available for human use. *Appl. Environ. Microbiol.* 2004;70:2161–2171. doi: 10.1128/AEM.70.4.2161-2171.2004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Endres JR, Clewell A, Jade KA, Farber T, Hauswirth J, Schauss AG. Safety assessment of a proprietary preparation of a novel probiotic, *Bacillus coagulans*, as a food ingredient. *Food Chem. Toxicol.* 2009;47:1231–1238. doi: 10.1016/j.fct.2009.02.018. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Elshaghabee FM, Rokana N, Gulhane RD, Sharma C, Panwar H. *Bacillus* as potential probiotics: status, concerns, and future perspectives. *Front. Microbiol.* 2017;8:1490. doi: 10.3389/fmicb.2017.01490. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
19. EFSA (European Food Safety Authority). Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. EFSA J. 10: 2740 (2012)
20. FAO/WHO. Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation. FAO Food and Nutrition Paper World Health Organization and Food Agriculture Organization of the United Nations (2006)
21. Fiorini G, Cimminiello C, Chianese R., II *B. subtilis* come stimolatore selettivo delle IgA linfocitarie di membrana. *Farmaci.* 1985; 9: 331–334. [Google Scholar]
22. Granchi L, Talini D, Rigacci S, Guerrini A, Berti A, Vincenzini M. Detection of putrescine-producer *Oenococcus oeni* strains by PCR. 8th Symposium on Lactic Acid Bacteria, The Netherlands (2006)
23. Granum PE, Lund T. *Bacillus cereus* and its food poisoning toxins. *FEMS Microbiol. Lett.* 1997;157:223–228. doi: 10.1111/j.1574-6968.1997.tb12776.x. [PubMed] [CrossRef] [Google Scholar]
24. Green DH, Wakeley PR, Page A, Barnes A, Baccigalupi L, Ricca E, Cutting SM. Characterization of two *Bacillus* probiotics. *Appl. Environ. Microbiol.* 1999;65:4288–4291. [PMC free article] [PubMed] [Google Scholar]
25. Guianane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. *Therap. Adv. Gastroenterol.* 2013;6:295–308. doi: 10.1177/1756283X13482996. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
26. Guinebretiere MH, Broussolle V, Nguyen-The C. Enterotoxigenic profiles of food-poisoning and food-borne *Bacillus cereus* strains. *J. Clin. Microbiol.* 2002;40:3053–3056. doi: 10.1128/JCM.40.8.3053-3056.2002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
27. Gul O, Athalar I. Different stress tolerance of spray and freeze dried *Lactobacillus casei* Shirota microcapsules with different encapsulating agents. *Food Sci. Biotechnol.* 2019;28:807–816. doi: 10.1007/s10068-018-0507-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
28. Hisieh YM, Sheu SJ, Chen YL, Tsen HY. Enterotoxigenic profiles and polymerase chain reaction detection of *Bacillus cereus* group cells and *B. cereus* strains from food-borne outbreaks. J. Appl. Microbiol. 87: 481-490 (1999) [PubMed]
29. Hoa NT, Baccigalupi L, Huxham A, Smertenko A, Van PH, Ammendola S, Ricca E, Cutting AS. Characterization of *Bacillus* species used for oral bacteriotherapy and bacterioprophylaxis of gastrointestinal disorders. *Appl. Environ. Microbiol.* 2000;66:5241–5247. doi: 10.1128/AEM.66.12.5241-5247.2000. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
30. Hoa NT, Duc LH, Isticato R, Baccigalupi L, Ricca E, Van PH, Cutting AS. Fate and dissemination of *Bacillus subtilis* spores in a murine model. *Appl. Environ. Microbiol.* 2001;67:3819–3823. doi: 10.1128/AEM.67.9.3819-3823.2001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
31. Hong HA, Duc LH, Cutting SM. The use of bacterial spore formers as probiotics. *FEMS Microbiol. Lett.* 2005;29:813–835. doi: 10.1016/j.femsre.2004.12.001. [PubMed] [CrossRef] [Google Scholar]
32. Hong HA, Huang JM, Khaneka R, Hiep LV, Urdaci MC, Urdaci MC, Cutting SM. The safety of *Bacillus subtilis* and *Bacillus indicus* as food probiotics. *J. Appl. Microbiol.* 2008;105:510–520. doi: 10.1111/j.1365-2672.2008.03773.x. [PubMed] [CrossRef] [Google Scholar]
33. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. *Science.* 2001;292:1115–1118. doi: 10.1126/science.1058709. [PubMed] [CrossRef] [Google Scholar]
34. Hyronimus B, Le Marrec C, Urdaci MC. Coagulin, a bacteriocin-like inhibitory substance produced by *Bacillus coagulans* $I_4$. *J. Appl. Microbiol.* 1998;85:42–50. doi: 10.1046/j.1365-2672.1998.00466.x. [PubMed] [CrossRef] [Google Scholar]
35. Jacquier V, Nelson A, Jlali M, Rhayat L, Brinch KS, Devillard E. *Bacillus subtilis* 29784 induces a shift in broiler gut microbiome toward butyrate-producing bacteria and improves intestinal histomorphology and animal performance. *Poult. Sci.* 2019;98:2548–2548. doi: 10.3382/ps/pey602. [PubMed] [CrossRef] [Google Scholar]

36. Jeon HL, Lee NK, Yang SJ, Kim WS, Paik HD. Probiotic characterization of *Bacillus subtilis* P223 isolated from kimchi. *Food Sci. Biotechnol.* 2017;26:1641–1648. doi: 10.1007/s10068-017-0148-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
37. Jeon HL, Yang SJ, Son SH, Kim WS, Lee NK, Paik HD. Evaluation of probiotic *Bacillus subtilis* P229 isolated from *cheonggukjang* and its application in soybean fermentation. *LWT-Food Sci. Technol.* 2018; 97: 94–99. doi: 10.1016/j.lwt.2018.06.054. [CrossRef] [Google Scholar]
38. Jung JH, Lee MY, Chang HC. Evaluation of the probiotic potential of *Bacillus polyfermenticus* CJ6 isolated from Meju, a Korean soybean fermentation starter. *J. Microbiol. Biotechn.* 2012;22:1510–1517. doi: 10.4014/jmb.1205.05049. [PubMed] [CrossRef] [Google Scholar]
39. Kanmani P, Satish Kumar R, Yuvaraja N, Paaria KA, Pattukumara V, Arula V. Probiotics and its functionally valuable products—a Review. *Crit. Rev. Food Sci. Nutr.* 2013;53:641–658. doi: 10.1080/10408398.2011.553752. [PubMed] [CrossRef] [Google Scholar]
40. Kawai K, Kamochi R, Oiki S, Murata K, Hashimoto W. Probiotics in human gut microbiota can degrade host glycosaminoglycans. *Sci. Rep.* 2018;8:10674. doi: 10.1038/s41598-018-28886-w. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
41. Kim MJ, Han JK, Park JS, Lee JS, Lee SH, Cho JI, Kim KS. Various enterotoxin and other virulence factor genes widespread among *Bacillus cereus* and *Bacillus thuringiensis* strains. *J. Microbiol. Biotechn.* 2015;25:872–879. doi: 10.4014/jmb.1502.02003. [PubMed] [CrossRef] [Google Scholar]
42. Kim SM, Lee KH, Lee NK, Kim CJ, Kim CH, Paik HD. Antagonistic activity of polyfermenticin SCD against *Helicobacter pylori* KCTC 2948. *J. Microbiol. Biotechn.* 2004;14:148–152. [Google Scholar]
43. Kotiranta A, Lounatmaa K, Haapasalo M. Epidemiology and pathogenesis of *Bacillus cereus* infections. *Microbes Infect.* 2000;2:189–198. doi: 10.1016/S1286-4579(00)00269-0. [PubMed] [CrossRef] [Google Scholar]
44. Landete JM, Ferrer S, Polo L, Pardo I. Biogenic amines in wines from three Spanish regions. *J. Agric. Food Chem.* 2005;53:1119–1124. doi: 10.1021/jf049340k. [PubMed] [CrossRef] [Google Scholar]
45. Lee KH, Jun KD, Kim WS, Paik HD. Partial characterization of polyfermenticin SCD, a newly identified bacteriocin of *Bacillus polyfermenticus*. *Lett. Appl. Microbiol.* 2001;32:146–151. doi: 10.1046/j.1472-765x.2001.00876.x. [PubMed] [CrossRef] [Google Scholar]
46. Lee MS, Lee NK, Chang KH, Choi SY, Song CK, Paik HD. Isolation and characterization of a protease-producing bacterium, *Bacillus amyloliquefaciens* P27 from *meju* as a probiotic starter for fermented meat products. Korean J. Food Sci. An. (2010)
47. Lee NK, Paik HD. Bioconversion using lactic acid bacteria: ginsenosides, GABA, and phenolic compounds. *J. Microbiol. Biotechn.* 2017;27:869–877. doi: 10.4014/jmb.1612.12005. [PubMed] [CrossRef] [Google Scholar]
48. Lee NK, Son SH, Jeon EB, Jung GH, Lee JY, Paik HD. The prophylactic effect of probiotic *Bacillus polyfermenticus* KU3 against cancer cells. *J. Funct. Foods.* 2015;14:513–518. doi: 10.1016/j.jff.2015.02.019. [CrossRef] [Google Scholar]
49. Le Marrec C, Hyronimus B, Bressollier P, Verneuil B, Urdaci MC. Biochemical and genetic characterization of coagulin, a new antilisterial bacteriocin in the pediocin family of bacteriocins, produced by *Bacillus coagulans* $I_4$. *Appl. Environ. Microbiol.* 2000;66:5213–5220. doi: 10.1128/AEM.66.12.5213-5220.2000. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
50. Linares DM, del Rio B, Redruello B, Ladero V, Martin MC, Fernandez M, Ruas-Madiedo P, Alvarez MA. Comparative analysis of the in vitro cytotoxicity of the dietary biogenic amines tyramine and histamine. *Food Chem.* 2016;197:658–663. doi: 10.1016/j.foodchem.2015.11.013. [PubMed] [CrossRef] [Google Scholar]
51. Lucas PM, Blancato VS, Claisse O, Magni C, Lolkema JS, Lonvaud-Funel A. Agmatine deiminase pathway genes in *Lactobacillus brevis* are linked to the tyrosine decarboxylation operon in a putative acid resistance locus. *Microbiology.* 2007;153:2221–2230. doi: 10.1099/mic.0.2007/006320-0. [PubMed] [CrossRef] [Google Scholar]
52. Ma EL, Choi YJ, Choi J, Pothoulakis C, Rhee SH, Im EE. The anti-cancer effect of probiotic *Bacillus polyfermenticus* on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. *Int. J. Cancer.* 2010;127:780–790. [PMC free article] [PubMed] [Google Scholar]

53. Ma Y, Wang W, Zhang H, Wang J, Zhang W, Gao J, Wu S, Qi G. Supplemental *Bacillus subtilis* DSM 32315 manipulates intestinal structure and microbial composition in broiler chickens. *Sci. Rep.* 2018;8:15358. doi: 10.1038/s41598-018-33762-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Mandel DR, Eichas K, Holmes J. *Bacillus coagulans*: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. *BMC Complement. Altern. Med.* 2010;10:1. doi: 10.1186/1472-6882-10-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
55. Marseglia GL, Tosca M, Cirillo I, Licari A, Leone M, Marseglia A, Castellazzi AM, Ciprandi G. Efficacy of *Bacillus clausii* spores in the prevention of recurrent respiratory infections in children: a pilot study. *Ther. Clin. Risk Manag.* 2007;3:13–17. doi: 10.2147/tcrm.2007.3.1.13. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
56. Matarante A, Baruzzi F, Cocconcelli PS, Morea M. Genotyping and toxigenic potential of *Bacillus subtilis* and *Bacillus pumilus* strains occurring in industrial and artisanal cured sausages. *Appl. Environ. Microbiol.* 2004;70:5168–5176. doi: 10.1128/AEM.70.9.5168-5176.2004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
57. Mazza P. The use of *Bacillus subtilis* as an antidiarrheal microorganism. *Boll. Chim. Farm.* 1994;133:3–18. [PubMed] [Google Scholar]
58. Muscettola M, Grasso G, Blach-Olszewska Z, Migliaccio P, Borghesi-Nicoletti C, Giarratana M, Gallo VC. Effects of *Bacillus subtilis* spores on interferon production. *Pharmacol Res.* 1992;2:176–177. doi: 10.1016/1043-6618(92)90652-R. [PubMed] [CrossRef] [Google Scholar]
59. Naila A, Flint S, Feltcher G, Bremer P, Meerdink G. Control of biogenic amines in food—existing and emerging approaches. *J. Food Sci.* 2010;75:R139–R150. doi: 10.1111/j.1750-3841.2010.01774.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
60. Mohan C, Arora R, Khalilullah M. Preliminary observation on effect of *Lactobacillus sporogenes* on serum lipid levels in hypercholesterolemic patients. *Indian J. Med. Res.* 1990;92:431–432. [PubMed] [Google Scholar]
61. Nicholson WL, Munakata N, Horneck G, Melosh HJ, Setlow P. Resistance of *Bacillus* endospores to extreme terrestrial and extraterrestrial environments. *Microbiol. Mol. Biol. Rev.* 2000;64:548–572. doi: 10.1128/MMBR.64.3.548-572.2000. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
62. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, Cammarota G, Gasbarrini G, Gasbarrini A. *Bacillus clausii* therapy to reduce side-effects of anti-*Helicobacter pylori* treatment: randomized, double-blind, placebo controlled trial. *Aliment. Pharmacol. Ther.* 2004;20:1181–1188. doi: 10.1111/j.1365-2036.2004.02274.x. [PubMed] [CrossRef] [Google Scholar]
63. Olmos J, Paniagua-Michel J. *Bacillus subtilis* a potential probiotic bacterium to formulate functional feeds for aquaculture. *J. Microb. Biochem. Technol.* 2014; 6: 361–365. doi: 10.4172/1948-5948.1000169. [CrossRef] [Google Scholar]
64. Paik HD, Park JS, Park E. Effects of *Bacillus polyfermenticus* SCD on lipid and metabolisms in rats fed a high-fat and high-cholesterol diet. *Biol. Pharm. Bull.* 2005;28:1270–1274. doi: 10.1248/bpb.28.1270. [PubMed] [CrossRef] [Google Scholar]
65. Park KY, Jung HY, Woo KL, Jun KD, Kang JS, Paik HD. Effects of *Bacillus polyfermenticus* SCD administration on fecal microflora and putrefactive metabolites in healthy adults. *J. Microbiol. Biotechn.* 2003;12:657–663. [Google Scholar]
66. Patrone V, Molinari P, Morelli L. Microbiological and molecular characterization of commercially available probiotics containing *Bacillus clausii* from India and Pakistan. *Int. J. Food Microbiol.* 2016;237:92–97. doi: 10.1016/j.ijfoodmicro.2016.08.012. [PubMed] [CrossRef] [Google Scholar]
67. Pinchuk IV, Bressollier P, Verneuil B, Fenet B, Sorokulova IB, Mégraud F, Urdaci MC. *In vitro* anti-*Helicobacter pylori* activity of the probiotic strain *Bacillus subtilis* 3 is due to secretion of antibiotics. *Antimicrob. Agents Chemother.* 2001;45:3156–3161. doi: 10.1128/AAC.45.11.3156-3161.2001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
68. Pirker A, Stockenhuber A, Remely M, Harrant A, Hippe B, Kamhuber C, Adelmann K, Stockenhuber F, Haslberger AG. Effects of antibiotic therapy on the gastrointestinal microbiota and the influence of *Lactobacillus casei*. *Food Agric. Immunol.* 2013;24:315–330. doi: 10.1080/09540105.2012.689816. [CrossRef] [Google Scholar]

69. Poulsen ASR, de Jonge N, Nielsen JL, Højberg O, Lauridsen C, Lauridsen S, Cutting SM, Canibe N. Impact of *Bacillus* spp. spores and gentamicin on the gastrointestinal microbiota of suckling and newly weaned piglets. PLOS ONE 13: e0207382 (2018) [PMC free article] [PubMed]
70. Sarkar A, Lehto SM, Harty S, Dinan TG, Cryan JF, Burnel PWJ. Psychobiotics and the manipulation of bacteria-gut-brain signals. *Trends Neurosci.* 2016;39:763–871. doi: 10.1016/j.tins.2016.09.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
71. Sanders ME, Morelli L, Tompkins TA. Sporeformers as human probiotics: *Bacillus*, *Sporolactobacillus*, and *Brevibacillus*. *Compr. Rev. Food Sci. Food Saf.* 2003;2:101–110. doi: 10.1111/j.1541-4337.2003.tb00017.x. [CrossRef] [Google Scholar]
72. SCAN. Opinion of the scientific committee on animal nutrition on the safety of use of *Bacillus* species in animal nutrition. European commission, health and consumer protection directorate-general. Scientific Committee on Animal Nutrition (SCAN) (2000)
73. Sorokulova I. Modern status and perspectives of *Bacillus* bacteria as probiotics. *J. Prob. Health.* 2013;1:4. doi: 10.4172/2329-8901.1000e106. [CrossRef] [Google Scholar]
74. Sorokulova IB, Pinchuk IV, Denayrolles M, Osipova IG, Huang JM, Cutting SM, Urdaci MC. The safety of two *Bacillus* probiotic strains for human use. *Dig. Dis. Sci.* 2008;53:954–963. doi: 10.1007/s10620-007-9959-1. [PubMed] [CrossRef] [Google Scholar]
75. Spano G, Russo P, Lonvaud-Funel A, Lucas P, Alexandre H, Grandvalet C, Coton E, Coton E, Barnavon L, Bach B, Rattray F, Bunte A, Magni C, Ladero V, Alvarez M, Fernńndez M, Lopez P, de Palencia PF, Corbi A, Trip H, Lolkema JS. Biogenic amines in fermented foods. *Eur. J. Clin. Nutr.* 2010;64:S95–S100. doi: 10.1038/ejcn.2010.218. [PubMed] [CrossRef] [Google Scholar]
76. Starosila D, Rybalko S, Varbanetz L, Ivanskaya N, Sorokulova I. Anti-influenza activity of *Bacillus subtilis* probiotic strain. *Antimicrob. Agents Chemother.* 2017;61:1–11. doi: 10.1128/AAC.00539-17. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
77. Stenfors Arnesen LP, Fagerlude A, Granum PE. From soil to gut: *Bacillus cereus* and its food poisoning toxins. *FEMS Microbiol. Rev.* 2008;32:579–606. doi: 10.1111/j.1574-6976.2008.00112.x. [PubMed] [CrossRef] [Google Scholar]
78. Suvarna S, Dsouza J, Ragavan ML, Das N. Potential probiotic characterization and effect of encapsulation of probiotic yeast strains on survival in simulated gastrointestinal tract condition. *Food Sci. Biotechnol.* 2018;27:745–753. doi: 10.1007/s10068-018-0310-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
79. Swapna B, Venkatrayulu Ch, Swathi AV. Effect of probiotic bacteria *Bacillus licheniformis* and *Lactobacillus rhamnosus* on growth of the Pacific white shrimp *Litopenaeus vannamei* (Boone, 1931) *Euro. J. Exp. Bio.* 2015;5:31–36. [Google Scholar]
80. Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem. J.* 2017;474:1832–1836. doi: 10.1042/BCJ20160510. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
81. Wang H, Huang J, Sun L, Xu F, Zhang W, Zhan J. An efficient process for co-production of γ-aminobutyric acid and probiotic *Bacillus subtilis* cells. *Food Sci. Biotechnol.* 2019;28:155–163. doi: 10.1007/s10068-018-0461-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
82. Yang HJ, Kwon DY, Kim HJ, Kim MJ, Jung DY, Kang HJ, Kim DS, Kang S, Moon NR, Shin BK, Park S. Fermenting soybeans with *Bacillus licheniformis* potentiates their capacity to improve cognitive function and glucose homeostaisis in diabetic rats with experimental Alzheimer's type dementia. *Eur. J. Nutr.* 2015 ;51: 77–88. doi: 10.1007/s00394-014-0687-y. [PubMed] [CrossRef] [Google Scholar]
83. Zhang YJ, Li S, Gan RY, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on human health and diseases. *Int. J. Mol. Sci.* 2015;16:7493–7519. doi: 10.3390/ijms16047493. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
84. Zhu K, Hölzel CS, Cui Y, Mayer R, Wang Y, Dietrich R, Didier A, Bassitta R, Märtlbauer E, Ding S. Probiotic *Bacillus cereus* strains, a potential risk for public health in China. *Front. Microbiol.* 2016;7:718. [PMC free article] [PubMed] [Google Scholar]